Property | Value |
?:abstract
|
-
BACKGROUND: Several molecular kits are available for SARS-CoV-2 diagnosis, mostly lacking of proper clinical evaluation due to the emergency caused by COVID19 pandemia, particularly at developing countries like Ecuador. OBJECTIVE: We carried out an evaluation of the clinical performance of \'AccuPower SARS-CoV-2 Real Time RT-PCR kit\' (Bioneer, South Korea) for SARS-CoV-2 diagnosis using 2019-nCoV CDC EUA kit (IDT, USA) as a gold standard. RESULTS: 48 clinical specimens were included on the study, 38 tested SARS-CoV-2 positive and 10 SARS-CoV-2 negative for 2019-nCoV CDC EUA kit. For \'AccuPower SARS-CoV-2 Real Time RT-PCR kit\', only 30 were SARS-CoV-2 positive, indicating a low clinical performance with sensitivity of 78.9%. Moreover, the limit of detection for \'AccuPower SARS-CoV-2 Real Time RT-PCR kit\' was estimated to be higher than 40,000 viral RNA copies/mL of sample. CONCLUSIONS: Proper clinical performance evaluation studies from government agencies at developing countries should be mandatory prior to clinical use authorization of SARS-CoV-2 diagnosis kits, particularly when those kits lack of either FDA or its country of origin clinical use authorization, to prevent the distribution of low quality products that may have a negative impact of COVID19 surveillance at developing countries.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1186/s12985-020-01445-4
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/e0fdcf4c58a10d357735bc43f7af3c35205a5669.json; document_parses/pdf_json/55f0560f73b9cfe3de78541e0eec06176df8de3c.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7666399.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Poor sensitivity of \'AccuPower SARS-CoV-2 real time RT-PCR kit (Bioneer, South Korea)\'
|
?:type
|
|
?:year
|
|